BTIG has initiated coverage on Sionna Therapeutics Inc (SION) with a Buy rating as of November 18, 2025. This marks the firm's first assessment of the company, which operates as a clinical-stage biopharmaceutical entity focused on developing novel medicines for cystic fibrosis.
Sionna Therapeutics, headquartered in Waltham, Massachusetts, is advancing a pipeline of small molecules aimed at correcting defects caused by the F508del genetic mutation. The company is conducting ongoing Phase I trials of its potent NBD1 stabilizers, SION-719 and SION-451, to evaluate their safety and pharmacokinetic profiles. Its portfolio also includes various CFTR modulators designed to enhance CFTR function, such as Galicaftor (SION-2222) and Navocaftor (SION-3067).
As of November 18, 2025, Sionna Therapeutics has a market capitalization of $1.7 billion and an earnings per share (EPS) of -2.23. The company is expected to report its next earnings on May 3, 2026, with an estimated EPS of -0.55.
Analyst ratings, including the recent Buy rating from BTIG, are based on research and financial models. While they provide insight into potential investment merit, they reflect assumptions that may change over time. Investors should consider various factors, including company fundamentals and industry trends, when making decisions.